Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of ME-401 in Subjects With CLL / SLL, FL, and B-cell Non-Hodgkin's Lymphoma

Multiple Cancer Types

A Three-Arm Study of ME-401 in Subjects with Relapsed / Refractory CLL / SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed / Refractory CLL / SLL or B-cell NHL
Leukemia, Lymphoma
I
Reddy, Nishitha
NCT02914938
VICCHEM1714

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed / Refractory T-cell Lymphoma

Lymphoma

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R / R T-cell lymphoma.
Lymphoma
I/II
Reddy, Nishitha
NCT03770000
VICCPCL1937

Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Lymphoma

Patients with high tumor burden, low grade follicular lymphoma that has never been treated, will receive venetoclax in combination with obinutuzumab and bendamustine. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with follicular lymphoma. Venetoclax may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding venetoclax to obinutuzumab and bendamustine improves the response (the tumor shrinks or disappears) in patients with follicular lymphoma. As of 9 / 5 / 2018, a higher than expected incidence of tumor lysis syndrome (TLS) was experienced among patients receiving venetoclax, obinutuzumab and bendamustine on Cycle 1, Day 1 of treatment. TLS is caused by the fast breakdown of cancer cells. These patients developed an increase in some of their blood tests (uric acid, phosphorus, potassium and / or creatinine). They received a medication called rasburicase and continued with treatment. It is unclear if the TLS was due to the venetoclax or the standard treatment of obinutuzumab and bendamustine. For the remaining patients, venetoclax will start on Cycle 2, Day 1 (previously Cycle 1, Day 1).
Lymphoma
II
Reddy, Nishitha
NCT03113422
VICCPCL17100

ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Lymphoma

This is the study of the PI3K? inhibitor ME-401 in subjects with relapsed / refractory follicular lymphoma after failure of at least 2 prior lines of systemic therapy
Lymphoma
II
Reddy, Nishitha
NCT03768505
VICCPCL1913

A Disease Registry of Patients With Mantle Cell Lymphoma

Lymphoma

The purpose of this study is to create a patient registry in order to assess treatment patterns, physician reported clinical outcomes and patient-reported health-related quality of life among patients diagnosed with Mantle Cell Lymphoma (MCL) who newly initiated a novel therapy in the past 3 months and treatment is ongoing at the time of enrollment.
Lymphoma
N/A
Reddy, Nishitha
NCT03816683
VICCPCL18150

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: